Search Results

Tolmar Inc., a fully integrated pharmaceutical company, announced results from a landmark survey of more than 300 US physicians, revealing barriers to treatment with testosterone-replacement therapy among patients and physicians that, if addressed, may improve patient care.

Clarus Therapeutics Holdings, Inc. (Clarus) (OTC: CRXTQ) announced today that, subject to entry into definitive documentation, it and its wholly-owned subsidiary, Clarus Therapeutics, Inc., selected Tolmar, Inc., (Buffalo Grove, IL) as the winning bidder in a competitive bidding and auction proceeding for the sale of JATENZO (and certain related assets).

Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).

Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that it has entered into a multi-year agreement with Tolmar Pharmaceuticals, Inc. to co-promote ALKINDI SPRINKLE®.

Nika Pharmaceuticals, Inc. introduces its plans to develop the company into a sustainable business project that will consistently grow, bring good profits and provide dividends to its shareholders.

Bexion Pharmaceuticals, Inc. announced that the Company will present at the 2024 Biotechnology Innovation Organization International Convention taking place June 3-6, 2024, in San Diego, California.

Future Pak, LLC and its affiliates announced that it has submitted a final attempt to engage with Vanda Pharmaceuticals Inc. in a good faith effort to acquire all outstanding shares of Vanda.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical stage pharmaceutical company, today announced that management will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on Thursday, June 27, 2024.